DRUG LEGALIZATION SERIES
PART 18
If you’re new to the series, start here.
Why drug policy keeps being written like a culture war when the real job is overdose prevention, less chaos, and faster access to help.
Executive Summary
Drug policy keeps getting written as if the main problem is symbolism.
Who looks disorderly.
Who scares suburban voters.
Who can be turned into a cautionary tale on television.
Who can be used as proof that society is collapsing.
That is not policy. That is moral panic.
A public health approach to drug policy starts from a completely different question: what reduces death, disease, disorder, and the distance between crisis and real help?
That matters because even after a major decline, the United States still recorded 79,384 drug overdose deaths in 2024.[1] If the baseline is still mass death, then culture-war messaging is not seriousness. It is avoidance.
This chapter makes a blunt argument.
• Drug policy reform fails when it is driven by disgust instead of evidence.
• Addiction stigma makes treatment harder to reach and easier to deny.[3][4]
• Harm reduction strategies belong inside a public-health model because they reduce immediate risk and create real paths into care.[2]
• Overdose prevention is not softness. It is what governments do when they value living citizens more than punitive theater.
• Risk-based drug regulation is the grown-up alternative to panic because it separates low-risk and high-risk lanes instead of pretending one rule fits everything.
Part 8 already argued that fear-based drug policy is still failing.
Part 11 argued for evidence-based prevention instead of propaganda.
Part 14 laid out the regulated pharmacy model for the highest-risk lane.
And the last two chapters pushed the same larger point from different angles: test policy like adults, and stop cherry-picking the evidence.
This chapter explains why that adult posture is still so hard to sustain politically.
The Policy Problem This Chapter Solves
The practical problem is not that policymakers do not know enough.
The practical problem is that drug policy keeps rewarding the wrong emotions.
A public health approach to drug policy asks:
• Who is dying?
• What substances and supply conditions are driving the deaths?
• What barriers keep people from treatment?
• Which harm reduction strategies reduce immediate risk?
• What mix of public safety, accountability, and care produces better outcomes?
A culture-war approach asks something else entirely:
• Who can be blamed?
• Which image will go viral?
• Which slogan sounds toughest?
• Which visible behaviors can be turned into proof of moral collapse?
That difference matters because a bad framing produces bad law.
If policymakers treat addiction as a morality play, they end up writing laws that are performative, punitive, and badly targeted. If they treat it as a public-health problem, they start thinking in terms of overdose prevention, treatment on demand, diversion control, and what actually lowers harm over time.
That is the split this chapter is about.
What Moral Panic Drug Policy Looks Like
Scholars describe moral panic as a process in which social threats are exaggerated in ways that assign blame and stigma to weaker or unpopular groups while downplaying structural causes.[13] That definition fits American drug policy uncomfortably well.
Moral panic drug policy usually has the same features every time.
It picks a villain.
It picks a visual.
It picks a slogan.
Then it writes policy around fear.
That is why our nation’s drug laws have been built around spectacle instead of systems.
A public health approach to drug policy does the opposite. It strips out the fantasy that punishment by itself will solve a market problem, a treatment-access problem, a trauma problem, or a contaminated-supply problem. It asks what reduces harm today and what improves stability tomorrow.
SAMHSA states it plainly: many people still believe addiction reflects a lack of willpower or moral principles, when in reality it is a complex disease that alters the brain and makes quitting hard even for people who want to stop.[3] CDC says stigma takes many forms, including treating substance use disorder as a moral issue instead of a medical one, and that stigma can block or delay treatment.[4]
That is not a side issue. That is the center of the problem.
Once the public is taught to see addiction as filth, weakness, or bad character, every evidence-based intervention starts looking like surrender. That is how addiction stigma turns policy into punishment theater.
Historical Examples of Moral Panic Drug Policy
American drug policy has done this before.
The crack era is one of the clearest examples. In its 1995 report to Congress, the U.S. Sentencing Commission said policymakers faced major information gaps, that research addressing outstanding concerns had not yet occurred, and that conclusions should therefore be drawn cautiously. Yet federal policy still built and defended the dramatic 100-to-1 quantity ratio between crack and powder cocaine.[5] That is what panic does: it fills evidence gaps with punitive certainty.
The meth panic followed a similar script. A study of newspaper coverage in three Midwestern cities found reporting that was disproportionate to the local scale of the meth problem and described the use of drug-scare rhetoric, including medical metaphors such as “plague,” that helped promote a moral panic over meth.[6]
The pattern is not gone. It just updates its vocabulary.
A 2024 paper warned that framing xylazine as a “zombie drug” amplifies stigma toward people who use drugs.[7] A 2025 randomized study went further and found that dehumanizing “zombie drugs” framing produced more stigmatizing attitudes toward people who use drugs.[8]
That is not harmless language. It is policy fuel.
Because once the public is told to see people as monsters, zombies, degenerates, or moral failures, it becomes easier to block harm reduction strategies, easier to dismiss overdose prevention, and easier to confuse humiliation with public safety.
This is also why Part 17 mattered. Real drug policy reform collapses when people cherry-pick case studies to flatter what they already wanted to believe. Panic does not just distort headlines. It distorts what evidence the public is even willing to hear.
What a Public Health Approach to Drug Policy Actually Looks Like
A public health approach to drug policy does not begin with outrage. It begins with triage.
Who is most likely to die?
What can reduce that risk now?
What care pathways are missing?
What rules protect the public without making treatment harder to reach?
That is where harm reduction strategies belong.
CDC defines harm reduction as a public-health approach aimed at reducing the harmful consequences of drug use, including infectious disease transmission and overdose prevention, through care that is free of stigma and centered on the needs of people who use drugs.[2] CDC also notes that syringe services programs can improve public safety through safe needle provision and disposal and are not associated with increased crime.[2]
That matters because the standard attack on harm reduction strategies is that they “enable” drug use.
CDC’s own stigma guidance names that belief directly as a form of stigma: withholding support or treatment because people assume helping someone means enabling them.[4]
That is a moral reflex, not an evidence-based one.
A public health approach to drug policy also treats access to care as infrastructure, not as an afterthought. SAMHSA’s advisory on low-barrier care says those models can overcome substantial gaps in access while engaging people in treatment.[9] NIDA says medications for opioid use disorder reduce the risk of overdose death and infectious disease behaviors, yet fewer than one in five people with opioid use disorder receive them.[10]
That is the real scandal.
Not that some people get naloxone.
Not that some people get sterile supplies.
Not that some people are met where they are.
The real scandal is that so many people die while the system still makes care harder to reach than moral judgment.
That is why a serious model has to include treatment on demand. It is why the highest-risk lane in this series keeps pointing toward a regulated pharmacy model instead of loose commercial access. And it is why drug legalization cannot be treated as one giant yes-or-no question. Different substances require different lanes, different safeguards, and different levels of structure.
How Addiction Stigma and Media Framing Keep Breaking Policy
The hardest part of a public health approach to drug policy is not designing it.
The hardest part is defending it against symbolism.
CDC reports that in 2022, 54.6 million people needed substance use treatment, but only 13.1 million received it.[4] CDC also says stigma can make it harder for people to get the help they need and may lead them to refuse, stop, or even be denied treatment.[4]
That is the operational cost of addiction stigma.
It changes language.
It changes clinician attitudes.
It changes what communities will tolerate.
It changes which policies sound “compassionate” and which ones sound “reckless,” even when the evidence points the other way.
NIDA’s guidance on language makes the same point in plain English: stigma and stigmatizing terms can portray people with substance use disorder in shameful or negative ways and may prevent them from seeking treatment.[12]
That is why media framing matters so much.
If the public sees “junkies,” “zombies,” “filth,” and “urban collapse,” then drug policy reform gets written like a battlefield memo. If the public sees untreated illness, contaminated supply, trauma, and blocked access to care, then a public health approach to drug policy has a fighting chance.
This is also where Part 13 on addiction and homelessness matters. Visible disorder is real, but visible disorder is not the whole problem and it is not the whole solution.
The political temptation is to treat what disgusts the public as the central problem. The public-health obligation is to treat what is killing people as the central problem.
Why Harm Reduction Strategies, Overdose Prevention, and Risk-Based Drug Regulation Belong Together
The culture-war version of this debate acts like governments have to choose between helping people and protecting communities.
That is false.
A serious system can do both.
Harm reduction strategies reduce immediate risk.
Overdose prevention keeps people alive long enough to reach recovery.
Risk-based drug regulation decides how tight each access lane should be based on real risk rather than ideology.
Public safety enforcement still targets violence, fraud, coercion, trafficking, sales to minors, and impaired driving.
Accountability still exists.
Diversion control still exists.
NHTSA is clear that driving impaired by drugs is illegal in all 50 states and the District of Columbia.[11] So no, a public-health model does not mean “no rules.” It means different rules aimed at actual harm.
That is the point of risk-based drug regulation. Lower-risk substances do not belong in the same lane as the highest-risk substances. The highest-risk lane needs more structure, not less. That is why this series keeps returning to the regulated pharmacy model for high-risk access and to treatment on demand as the non-negotiable exit ramp.
This is where drug policy reform has to stop acting like nuance is weakness.
A public-health model should be:
• softer on possession than prohibition
• harder on contaminated supply
• harder on sales to minors
• harder on violence and fraud
• serious about diversion control
• serious about overdose prevention
• serious about accountability
That is not contradiction. That is design.
And it is why risk-based drug regulation beats panic. Panic only knows how to swing a hammer. Risk-based drug regulation can actually distinguish between a low-risk retail lane, a tightly controlled high-risk medical lane, and conduct that still deserves aggressive enforcement.
The Bottom Line
The problem is not that drug policy is too compassionate.
The problem is that it keeps getting written by people who confuse disgust with wisdom.
A public health approach to drug policy does not deny risk. It measures it. It separates it. It manages it. It asks what reduces death, what reduces chaos, what improves public safety, and what gets people into real care.
That means:
• less addiction stigma
• more harm reduction strategies
• more overdose prevention
• more evidence-based prevention
• more treatment on demand
• more visible accountability
• stronger diversion control where risk is high
• and tighter, smarter lanes through risk-based drug regulation
That is the adult alternative to moral panic.
Frequently Asked Questions
What is a public health approach to drug policy?
A public health approach to drug policy treats drug use, addiction, overdose, and contaminated supply as health and systems problems, not just as moral failures or crimes. It focuses on prevention, treatment, harm reduction strategies, and targeted public safety enforcement.
Why is addiction stigma such a big policy problem?
Because addiction stigma changes how the public, clinicians, and lawmakers respond. It makes people less likely to seek help and makes others more willing to withhold help.[3][4][12]
Are harm reduction strategies just another word for permissiveness?
No. Harm reduction strategies are evidence-based tools that reduce immediate harm, support overdose prevention, and create links to treatment. They are a public-health response, not a free-for-all.[2]
How does risk-based drug regulation fit into this chapter?
Risk-based drug regulation is the alternative to one-size-fits-all thinking. It says higher-risk substances require tighter channels, stronger safeguards, and better diversion control, while lower-risk substances can be governed differently.
Does a public-health model ignore public safety?
No. A public-health model still enforces laws against violence, trafficking, fraud, sales to minors, and impaired driving. It just stops pretending that punishing simple possession is the best answer to every drug problem.[11]
Why does this series keep coming back to the regulated pharmacy model?
Because the regulated pharmacy model is the narrowest and most auditable way to handle a high-risk lane. It fits the larger logic of risk-based drug regulation, accountability, and treatment on demand.
References
[1] Centers for Disease Control and Prevention, National Center for Health Statistics. U.S. Life Expectancy Hits Record High as Drug Overdose Deaths Decline in 2024. https://www.cdc.gov/nchs/pressroom/releases/20260129.html
[2] Centers for Disease Control and Prevention. Overdose Data to Action: Prevention Strategies. https://www.cdc.gov/overdose-prevention/php/od2a/prevention.html
[3] Substance Abuse and Mental Health Services Administration. Substance Use Disorder – Causes, Symptoms, Treatment & Help. https://www.samhsa.gov/substance-use
[4] Centers for Disease Control and Prevention. Stigma Reduction. https://www.cdc.gov/stop-overdose/stigma-reduction/index.html
[5] United States Sentencing Commission. 1995 Report to the Congress: Cocaine and Federal Sentencing Policy. https://www.ussc.gov/research/congressional-reports/1995-report-congress-cocaine-and-federal-sentencing-policy
[6] Weidner RR. Methamphetamine in Three Small Midwestern Cities: Evidence of a Moral Panic. https://pubmed.ncbi.nlm.nih.gov/19999676/
[7] Bowles JM, Copulsky EC, Reed MK. Media framing xylazine as a “zombie drug” is amplifying stigma onto people who use drugs. https://pubmed.ncbi.nlm.nih.gov/38364357/
[8] Sumnall HR, Holland A, Atkinson AM, Montgomery C, Nicholls J, Maynard OM. “Zombie drugs”: Dehumanising news frames and public stigma towards people who use drugs. https://pubmed.ncbi.nlm.nih.gov/39827740/
[9] Substance Abuse and Mental Health Services Administration. Advisory: Low Barrier Models of Care for Substance Use Disorders. https://library.samhsa.gov/product/advisory-low-barrier-models-care-substance-use-disorders/pep23-02-00-005
[10] National Institute on Drug Abuse. Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
[11] National Highway Traffic Safety Administration. Drug-Impaired Driving. https://www.nhtsa.gov/risky-driving/drug-impaired-driving
[12] National Institute on Drug Abuse. Words Matter: Terms to Use and Avoid When Talking About Addiction. https://nida.nih.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction
[13] Eversman MH, Bird JDP. Moral Panic and Social Justice: A Guide for Analyzing Social Problems. https://pubmed.ncbi.nlm.nih.gov/28395037/
